Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple Sclerosis
Open Access
- 16 June 2025
- journal article
- research article
- Published by Springer Nature in Neurology and Therapy
- Vol. 14 (4) , 1627-1639
Abstract
Introduction Multiple sclerosis (MS) is a heterogeneous disease that disproportionately impacts Black people with MS (PwMS), who experience more severe disease and higher relapse rates compared with non-Black populations. Despite widespread use of fumarates and sphingosine-1-phosphate (S1P) receptor modulators as oral disease-modifying therapies (DMTs) for relapsing MS, their comparative effectiveness in Black PwMS has not been studied. This study aims to help address this gap using real-world claims data. Methods This retrospective analysis using the Komodo Health Claims Database included Black PwMS. Patients were aged 18–64 years with ≥ 1 claim for MS diagnosis (International Classification of Diseases, Tenth Revision, Clinical Modification code G35) and ≥ 1 prescription claim for fumarates (dimethyl fumarate or diroximel fumarate) or an S1P receptor modulator (fingolimod, siponimod, ozanimod, or ponesimod) between January 2017 and April 2023. Outcomes included annualized relapse rate (ARR) and time to first relapse. Propensity score matching (2:1) and inverse probability weighting were used to balance baseline characteristics. Relapse events were identified using a claims-based algorithm. Results The analysis included 1664 Black PwMS (1231 and 433 in fumarate and S1P treatment arms, respectively). Post-index ARRs were comparable between groups (rate ratio [RR] 1.18, p = 0.423). Kaplan–Meier analyses showed similar relapse-free proportions at 24 months (72.6% and 74.7% in fumerate and S1P populations, respectively; p = 0.152). These findings were consistent in both the propensity score-matched and inverse probability weighted populations. Conclusions This real-world, claims-based analysis demonstrates that fumarates and S1P receptor modulators have similar effectiveness in reducing relapses among Black PwMS, with > 72% of patients in both treatment groups remaining relapse-free at 24 months. Given the underrepresentation of Black patients in MS clinical trials, these results provide valuable real-world evidence to guide treatment decisions for this population.Keywords
Funding Information
- Biogen
This publication has 23 references indexed in Scilit:
- Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple SclerosisCNS Drugs, 2023
- Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing–Remitting Multiple Sclerosis: STRIVE Data AnalysisNeurology and Therapy, 2023
- Social determinants of health in multiple sclerosisNature Reviews Neurology, 2022
- Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010–2019Neurology and Therapy, 2022
- Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying TherapyDrugs - Real World Outcomes, 2021
- Use of a claims-based algorithm to estimate disease severity in the multiple sclerosis Medicare populationMultiple Sclerosis and Related Disorders, 2021
- Replication of a Claims-based Algorithm to Estimate Multiple Sclerosis Disease Severity in a Commercially Insured PopulationMultiple Sclerosis and Related Disorders, 2020
- Clinical Characteristics of Multiple Sclerosis in African-AmericansCurrent Neurology and Neuroscience Reports, 2019
- Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the USMultiple Sclerosis and Related Disorders, 2019
- Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registryJournal of Neurology, 2018